Vir Biotechnology Inc expected to post a loss of $1.21 a share - Earnings Preview

Vir Biotechnology

01/11/2023 02:46

* Vir Biotechnology Inc  VIR.OQ   VIR.O  is expected to show
a
fall in quarterly revenue when it reports  results 
    * The San Francisco California-based  company is expected to
report  a 97.3% decrease in revenue to $10.236 million from
$374.56 million a year ago, according to the mean estimate from
6 analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Vir Biotechnology
Inc is
for a loss of $1.21 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vir
Biotechnology
Inc is $23.5​, above​ its last closing price of $7.93. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -1.19       -1.20      -1.45     Missed  -20.5
 Mar. 31 2023  -0.74       -0.87      -1.06     Missed  -21.2
 Dec. 31 2022  -0.25       -0.39      -0.76     Missed  -92.4​
 Sep. 30 2022  -0.21       -0.21      1.30      Beat    710.3
 ​​Jun.        0.16        0.10       -0.58     Missed  -653.7
 30 2022                                                
 Mar. 31 2022  3.83        3.78       3.85      Beat    1.9​
 Dec. 31 2021  4.42        3.04       3.92      Beat    28.9
 Sep. 30 2021  0.04        0.02       0.82      Beat    3,487.
                                                        1
 This summary was machine generated November 1 at 02:45 GMT.  All
figures in US dollars  unless otherwise stated